12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Company News  |  Deals

Celgene, VentiRx deal

VentiRx granted Celgene an exclusive option to acquire the company following Phase II data of VTX-2337 in ovarian or head and neck cancer. VentiRx will receive $35 million up front and is eligible for undisclosed additional...

Read the full 170 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >